Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Long-term data back UAE (uterine artery embolisation) Embosphere therapy:

This article was originally published in Clinica

Executive Summary

BioSphere Medical has reported positive results from what it claims is the first study to assess the long-term safety and efficacy of its Embosphere microspheres in the treatment of uterine artery embolisation (UAE). A follow-up at one, six and 12-months of 20 patients who received the treatment showed that symptoms of severe bleeding were resolved in 19 of them and improved in the 20th patient, revealed data from a European study. The Rockland, Massachusetts company markets the microspheres for general embolisation therapy in Europe, where they are also available for UAE therapy, and in the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT074933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel